



Thiazolidinediones – Emerging Evidence on Bone Formation

a report by

Jaime A Davidson

Clinical Professor of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical School, Dallas

DOI:10.17925/EE.2007.00.02.37

The thiazolidinediones (TZDs) – of which the two most frequently prescribed are rosiglitazone and pioglitazone – are insulin-sensitising oral antidiabetic agents that are an effective treatment for type 2 diabetes. The primary pharmacological actions of these drugs are to increase adipose and muscle insulin sensitivity and to inhibit gluconeogenesis in the liver. In type 2 diabetes patients, rosiglitazone reduces plasma levels of fasting glucose, glycated haemoglobin (HbA_{1c}) and insulin.¹ It may also improve β -cell function.² However, emerging evidence regarding the relationship between the use of TZDs and bone loss in type 2 diabetes patients gives cause for concern.³

There is an increased risk of bone fractures in patients with type 2 diabetes. Some – although not all – studies have shown higher rates of fracture in people with type 2 diabetes compared with normal

...emerging evidence regarding the relationship between the use of thiazolidinediones and bone loss in type 2 diabetes patients gives cause for concern.

individuals. The Health, Aging and Body Composition (Health ABC) Study showed that elderly white women with type 2 diabetes (but not elderly men or black women) had more rapid bone loss at the femoral neck and total hip than those with normal glucose homeostasis.⁴ This was despite having higher bone mineral density (BMD) at baseline. These data suggest that elderly white women with type 2 diabetes are at a greater risk of hip fracture than the normal population, and more so than men or black women with the disease. There is already a higher prevalence of fracture risk in the elderly population as a whole and bone loss could put older patients with type 2 diabetes at an even higher risk of fracture.

Data from the Study of Osteoporotic Fractures (SOF) reported by Taylor et al.⁵ showed that although hip BMD is strongly related to hip-fracture risk in elderly white women, there are a number of other clinical risk factors that are independent predictors of long-term risk (e.g. more frequent falls, poor balance, diabetes complications, etc.). This is an important consideration when assessing risk in diabetes patients, and suggests that a wider viewpoint should be embraced.

Lipscombe et al.⁶ examined the risk of hip fractures among elderly men and women with type 2 diabetes using population-based Ontario

healthcare data. They showed that fracture risk is increased in both men and women with type 2 diabetes compared with normoglycaemic individuals, despite a higher BMD in the diabetes group.

A prospective study by Bonds et al.⁷ compared women diagnosed with type 2 diabetes with those without diagnosed diabetes using a cohort of post-menopausal women who were part of the Women's Health Initiative Observational Study. The aim was to determine the risk of fracture and to establish whether risk varies according to fracture site, ethnicity and baseline BMD. After seven years of follow-up, the overall risk of fracture was higher in women with type 2 diabetes at baseline (after controlling for a range of other risk factors, including frequency of falls). Where BMD had been measured at baseline, women with diabetes had greater hip and spine BMD. Analysis of the data by race (non-Hispanic white versus black women) showed a slightly higher risk of any fracture for black women with diabetes compared with non-Hispanic white women. The study showed that post-menopausal women with type 2 diabetes are at increased risk of fractures, with a 20% increased risk of having a fracture during an average seven years of follow-up. Women with diabetes had a 46% increased risk of a fracture of the hip/pelvis/upper leg, and were approximately 30% more likely to report a fracture of the foot or spine. These data remained significant even after adjustment for other risk factors.

TZDs have been reported to cause bone loss in some rodent models,⁸⁻⁹ but information is scarce regarding their effect on human BMD. Schwartz et al.³ carried out a further analysis of the four-year follow-up data from the Health ABC Study to determine whether the use of TZDs is associated with changes in BMD in older adults with type 2 diabetes. Their findings indicated that TZDs may cause bone loss at the whole body, lumbar spine and trochanter in older women, but not in men. Ethnic differences were not examined. Since bone loss is a potent predictor of fracture risk, TZD use may be associated with an increase



Jaime A Davidson is Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School and President of Endocrine and Diabetes Associates of Texas. Dr Davidson was one of the charter members in the formation of the American Association of Clinical Endocrinologists (AACE). He is presently a member of the Texas Diabetes Council Professional Committee for the Texas Department of Health. He is also a Member of the Council on Obesity Diabetes Education and the International Diabetes Federation Task

Force on Epidemiology and a Trustee of the American College of Endocrinology (ACE), and is on the President's Council on Physical Fitness and Safety. He has received numerous awards; most recently, he was presented with the Outstanding Service Award for the Promotion of Endocrine Health of an Underserved Population for his work in addressing health disparities in Hispanic and Latino communities during the American Diabetes Association (ADA) meeting.

E: jdavison@medicalcitydallas.com



in burden on skeletal health in a population that already has a higher risk of fracture.

Conversely, the existence of a relationship between type 1 diabetes and low bone mass compared with normoglycaemic subjects is well established.^{10–12} In patients with recent-onset type 1 diabetes, bone loss may be due to the absence of the anabolic effects of insulin, and in patients with long-term disease vascular complications may contribute to low bone mass and fracture risk. Impaired glucose function is detrimental to bone metabolism, and this may be the cause of the decrease in BMD and the increased risk of fractures associated with the disease.

Most published studies have focused on patients who have been suffering from type 1 diabetes for many years and already have disease complications. A study by Lopez-Ibarra et al.¹¹ focused on the

Complications of diabetes may also contribute to fracture risk, especially in patients with neuropathy. Alternatively, diabetes may be associated with an increase in the likelihood of falls and other traumas.

status of BMD and bone remodelling factors in 32 subjects at the time of diagnosis. They showed that a high percentage of patients with type 1 diabetes already had a loss of both cortical and trabecular bone at outset, indicating that it cannot be a late complication of the disease. The BMD values did not correlate with bone remodelling markers, HbA_{1c} values or immunological variables. It can be assumed that cell destruction and insulinopenia begin well before the clinical onset of the disease. This was a small study that needs confirmation with larger numbers of subjects.

Campos-Pastor et al.¹⁰ investigated the possible effects of poor metabolic control and diabetes evolution time on bone loss in a group of 62 type 1 diabetes patients (previously classified as normal, osteopenic or osteoporotic) before, and seven years after, starting intensive insulin therapy. The overall outcome of the study was a stabilisation of BMD at all sites, a significant increase in body mass index (BMI) – which could help to stabilise BMD – and a reduction in HbA_{1c} values and bone resorption parameters. Improvement in metabolic control may therefore contribute to the stabilisation of bone mass and allay the progression of osteopenia. However, despite intensive insulin therapy, those patients with retinopathy had a reduced BMD and higher HbA_{1c} values than those without retinopathy, suggesting an association between bone loss and poor metabolic control in type 1 diabetes.

Vestergaard¹³ used meta-analysis to investigate differences between type 1 and type 2 diabetes with respect to BMD and fracture risk. Hip fracture risk was shown to be increased in both type 1 and type 2 diabetes compared with individuals without diabetes. The increase in relative hip-fracture risk was significantly higher in type 1 than type 2 diabetes

patients. BMD was decreased in the spine and hip in type 1 diabetes patients, and increased in the spine and hip in type 2 diabetes patients. A meta-regression showed that BMI was a major determinant for BMD in both the spine and the hip.

Insulin is an anabolic hormone, and patients with type 1 diabetes are insulin-deficient, whereas type 2 diabetes is due to a decrease in sensitivity to insulin in peripheral tissues. As a result, there may be an excess of insulin. Animal models have shown that although bone density is increased in diabetes, bone structure is more fragile. Hyperglycaemia causes an alteration in the glycosylation of collagen, producing advanced glycosylation end-products (AGEs) and their receptors (RAGEs), which affect bone metabolism and increase bone fragility. Complications of diabetes may also contribute to fracture risk, especially in patients with neuropathy. Alternatively, diabetes may be associated with an increase in the likelihood of falls and other traumas.

Evidence from Animal Studies

The TZDs are high-affinity synthetic ligands of the peroxisome-proliferators-activated receptor- γ (PPAR- γ),^{14–15} the activation of which alters the transcription of genes involved in glucose uptake, glucose utilisation and lipid metabolism. PPAR- γ , which belongs to a family of nuclear receptor transcription factors, occurs as two isoforms – PPAR- γ 1, which is expressed in many cell types (including adipocytes, osteoblasts, muscle cells and macrophages), and PPAR- γ 2, which is specific for adipocytes.

The PPAR- γ 2 receptor is known to play a role in marrow adipocyte differentiation and fat deposition, and appears to be critical for the regulation of osteoblast and adipocyte differentiation from common mesenchymal stromal cell/stem-cell bone marrow progenitors.⁸ PPAR- γ is a positive regulator of marrow adipocyte formation and a negative regulator of osteoblast development. *In vivo*, an increase in PPAR- γ activity leads to bone loss and a decrease in activity leads to increased bone mass. In the presence of PPAR- γ , rosiglitazone converts cells of the osteoblast lineage to adipocytes and simultaneously suppresses the osteoblast.^{16–17}

TZDs have been reported to cause bone loss in some rodent models.^{8–9} The effect of rosiglitazone on mouse bone has been the subject of a number of studies *in vivo*. Rzonca et al.⁸ treated six-month-old male non-diabetic C57BL/6 mice for seven weeks with rosiglitazone and demonstrated a significant decrease in total body BMD. Analysis of the micro-architecture of the bone showed changes in bone morphology and structure that were accompanied by changes in the expression of osteoblast- and adipocyte-specific marker genes. The authors concluded that their findings indicate that mouse bone marrow is a target for rosiglitazone, and that rosiglitazone therapy may affect human bone and be a risk for adverse skeletal effects in type 2 diabetes patients who are prescribed TZDs.

Another *in vivo* study by Soroceanu et al.¹⁸ also demonstrated that rosiglitazone treatment affected bone loss in a mouse model. It was shown that rosiglitazone-treated mice had increased weight compared with controls, but no significant alteration in serum glucose levels, calcium or parathyroid hormone. The BMD of rosiglitazone-treated mice was lower at the lumbar vertebrae, ilium/sacrum and total body compared with controls. Trabecular bone in the treated

animals was decreased, marrow space was increased and there was no significant change in bone-marrow adiposity. It was concluded that the imbalance in bone remodelling caused by rosiglitazone treatment was due to increased apoptotic death of osteogenic cells and reduced bone formation, leading to a decrease in trabecular bone volume and BMD.

In contrast, Sottile et al.⁹ investigated the impact of rosiglitazone treatment on bone tissue of intact and ovariectomised skeletally mature female rats, and showed no change in bone mass or fat marrow volume in intact rats treated for eight weeks with rosiglitazone. However, rosiglitazone administered for 12 weeks to ovariectomised rats enhanced bone loss and increased fat marrow volume compared with vehicle-treated ovariectomised controls. Osteoblast number was similar in both groups. Bone resorption parameters were increased, and enhanced bone loss was present in the tibia, femur and lumbar spine of the ovariectomised treated rats. Thus, the researchers showed no effect of rosiglitazone on bone loss in intact rats, but suggested that TZDs may enhance bone loss induced by oestrogen deprivation.

The cellular basis underlying the response of the skeleton to rosiglitazone was investigated by Ali et al.,¹⁹ who showed that adult mice receiving rosiglitazone experience bone loss characterised by an increase in marrow adipocytes, a decrease in the osteoblast/osteoclast ratio and a reduction in wall width and bone-formation rate. They also showed that rosiglitazone diverted bipotential mesenchymal progenitors from the osteoblast to the adipocyte lineage and suppressed the differentiation of monopotent osteoblast progenitors. Bone loss caused by rosiglitazone is due, at least in part, to a reduction in the differentiation of osteoblasts from early progenitors.

A Diabetes Outcome and Progression Trial

ADOPT (A Diabetes Outcome and Progression Trial) was a multicentre, randomised, double-blind, parallel-group study of 4,360 patients with recently diagnosed type 2 diabetes.²⁰ It examined the efficacy of monotherapy with rosiglitazone, metformin or glyburide as an initial treatment for maintaining long-term glycaemic control in this group. The patients were followed for a period of four to six years, thus comparing three commonly used antidiabetic drugs over an extended

Further examination of ADOPT data by Kahn et al. showed that women treated with rosiglitazone suffered more fractures than those receiving metformin or glyburide (9.3 versus 5.1 and 3.5%, respectively).

time period. The primary outcome of the trial was the time to treatment failure, defined as a fasting blood glucose level in excess of 10mmol/l after an overnight fast. The results, as reported by Kahn et al.²⁰ using Kaplan-Meier analysis, showed a cumulative incidence of treatment

failure at five years of 15% with rosiglitazone, 21% with metformin and 34% with glyburide, which represented a risk reduction of 32% for rosiglitazone compared with metformin, and 63% compared with glyburide. Thus, according to this trial, initial treatment of type 2 diabetes with rosiglitazone (over a median four-year period) slowed progression to monotherapy failure more effectively than either metformin or glyburide. Rosiglitazone was, however, associated with a higher risk of cardiovascular events than glyburide and with more weight gain and oedema than either metformin or glyburide, but with fewer gastrointestinal events than metformin and less hypoglycaemia than glyburide.

Further examination of the ADOPT data by Kahn et al. showed that women treated with rosiglitazone suffered more fractures than those receiving metformin or glyburide (9.3 versus 5.1 and 3.5%,

Since thiazolidinediones are used with increasing frequency to treat type 2 diabetes, it is important to know whether these drugs cause bone damage in this group of patients, but at present the available information is only observational.

respectively). The fractures were mainly of the upper arm, hand or foot, which are different sites from those seen with post-menopausal osteoporosis, which involve the hip or spine. Among male patients, the observed incidence of fractures was similar within the three treatment groups. Fractures of the hip or spine were low in women patients and similar within the three treatment groups. As a result, GlaxoSmithKline, in consultation with Health Canada, sent a letter to healthcare professionals to inform them of these findings (available at http://www.fda.gov/medwatch/safety/2007/Avandia_GSK_Ltr.pdf).

It is essential to maintain near-normal glycaemia in type 2 diabetes patients in order to reduce the risk of long-term complications, but the progressive nature of the disease, mainly due to declining β -cell function, makes this goal difficult to achieve and generally requires the use of increased drug dosage, combination therapies or insulin. In ADOPT, rosiglitazone slowed the decline in β -cell function and improved insulin sensitivity compared with metformin and glyburide, which indicates that TZDs may provide more effective treatment in the early stages of type 2 diabetes; however, the potential risk of bone fractures associated with their use, particularly in women, may outweigh their benefits. Healthcare professionals should therefore take into account the risk of fracture, particularly when initiating treatment of women with type 2 diabetes with rosiglitazone.

Emerging Evidence from Randomised Controlled Trials

Since TZDs are used with increasing frequency to treat type 2 diabetes, it is important to know whether these drugs cause bone damage in this group of patients, but at present the available information is only observational.

Grey et al.²¹ set out to determine whether rosiglitazone had adverse skeletal effects in healthy post-menopausal women. The study was a randomised, double-blind, placebo-controlled study of 14 weeks involving 50 healthy post-menopausal women. The primary end-points were two specific markers of bone formation (procollagen type I N-terminal peptide (PINP) and osteocalcin) and secondary end-points

Since most studies so far have focused on elderly patients, trials with younger patients are paramount.

were a bone resorption marker (β -C-terminal telopeptide, β CTX) and BMD. PINP and osteocalcin in the women taking rosiglitazone fell by 13 and 10%, respectively, compared with placebo treatment. These changes were evident at four weeks and continued for the duration of the study. There was, however, no change in the bone resorption marker β CTX ($p=0.9$ versus placebo). Total hip BMD decreased in the group receiving rosiglitazone. The mean changes from baseline were: rosiglitazone -1.9%; placebo 0.2%; between-group difference 1.7%; 95% confidence interval (CI) 0.6–2.7 ($p<0.01$). Lumbar spine density fell from baseline values in the rosiglitazone group ($p=0.02$ versus baseline), but was not significantly different between groups (mean change from baseline for rosiglitazone was -1.2%; placebo -0.2%; between-group difference 1.0%; 95% CI -0.2–2.3 ($p=0.13$)).

Thus, short-term therapy with rosiglitazone inhibits bone formation and accelerates bone loss, thereby causing damaging skeletal effects in healthy post-menopausal women. Since patients with type 2 diabetes may have an increased risk of bone fractures, the possibility that TZDs may increase the risk is important. The authors suggest that skeletal end-point markers should be included in any future long-term studies of TZD therapy.

Summary and Discussion

Type 2 diabetes patients are at increased risk of fracture despite having a higher BMD than individuals with normal glucose metabolism. Elderly white women appear to be more at risk than men or black women. The TZD rosiglitazone is an effective and commonly prescribed treatment for type 2 diabetes, but early evidence suggests that it may lead to bone loss and fractures, particularly of the hip, in elderly type 2 diabetes patients. Analysis of data from ADOPT showed that although rosiglitazone was the more effective drug in maintaining glycaemic control, its use was associated with more fractures than treatment with either metformin or glyburide. The fracture sites differed from those seen with post-menopausal osteoporosis and in other reported studies where the hip was the main fracture site. Thus, inconsistencies exist that should be investigated further.

There have been no large specifically designed clinical studies to address the relationship between TZDs and fracture risk in type 2 diabetes patients. Furthermore, in the observational studies so far, only rosiglitazone has been considered. It is now essential to design and implement randomised clinical trials to test whether TZDs affect bone metabolism and cause fractures in type 2 diabetes patients and to investigate whether choice of drug, age, gender and ethnicity are important. In elderly people, particularly women, there is an increased risk of fracture from, for example, falls, poor balance and visual impairment, and these factors should be assessed in the context of the trial. Since most studies so far have focused on elderly patients, trials with younger patients are paramount.

The evidence from animal studies suggests that rosiglitazone therapy might pose a significant risk to human bone and opens up the possibility of developing selective antidiabetic PPAR- γ agonists without adverse effects on bone.

The global prevalence of diabetes in 2000 was estimated at approximately 170 million, and is predicted to double by 2030.²² Thus, even a small increase in hip-fracture risk among diabetes patients will have a significant financial impact on healthcare provision.

Healthcare professionals need to be informed of the potential risk of prescribing TZDs to type 2 diabetes patients, and these patients should be carefully monitored during the progress of their treatment. ■

1. Kahn RC, Chen L, Cohen SE, Unraveling the mechanism of action of thiazolidinediones, *J Clin Invest*, 2000;106:1305–7.
2. Werner AL, Travaglini MT, A review of rosiglitazone in Type 2 diabetes mellitus, *Pharmacotherapy*, 2001;21:1082–99.
3. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al., Thiazolidinedione use and bone loss in older diabetic adults, *J Clin Endocrinol Metab*, 2006;91:3349–54.
4. Schwartz AV, Sellmeyer DE, Strotmeyer ES, et al., Diabetes and bone loss at the hip in older black and white adults, *J Bone Miner Res*, 2005;20:596–603.
5. Taylor BC, Schreiner PJ, Stone KL, et al., Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures, *J Am Geriatr Soc*, 2004;52:1479–86.
6. Lipscombe LL, Jamal SA, Booth GL, Hawker GA, The risk of hip fracture in older individuals with diabetes, *Diabetes Care*, 2007;30:835–41.
7. Bonds DE, Larson JC, Schwartz AV, et al., Risk of fracture in women with Type 2 diabetes: the Women's Health Initiative Observational Study, *J Clin Endocrinol Metab*, 2006;91:3404–10.
8. Rzonca SO, Suva LJ, Gaddy D, et al., Bone is a target for the antidiabetic compound rosiglitazone, *Endocrinology*, 2004;145:401–6.
9. Sottile V, Seuwen K, et al., Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPAR gamma agonist BRL49653 (rosiglitazone), *Calcif Tissue Int*, 2004;75:329–37.
10. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, et al., Intensive insulin therapy and bone mineral density in Type 1 diabetes mellitus: a prospective study, *Osteoporos Int*, 2000;11:455–9.
11. Lopez-Ibarra PJ, Pastor MM, Escobar-Jimenez F, et al., Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus, *Endocr Pract*, 2001;7:346–51.
12. Kemink SA, Hermus AR, Swinkels LM, et al., Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology, *J Endocrinol Invest*, 2000;295–303.
13. Vestergaard P, Discrepancies in bone mineral density and fracture risk in patients with Type 1 and Type 2 diabetes – a meta-analysis, *Osteoporos Int*, 2007;18:427–44.
14. Lehmann JM, Moore LB, Smith-Oliver TA, et al., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma), *J Biol Chem*, 1995;270:12953–6.
15. Hauner H, The mode of action of thiazolidinediones, *Diabetes Metab Res Rev*, 2002;18:S10–15.
16. Lecka-Czernik B, Gubrij I, Moerman EJ, et al., Inhibition of *Osf2/Cbfa1* expression and terminal osteoblast differentiation by PPAR γ 2, *J Cell Biochem*, 1999;74:357–71.
17. Lecka-Czernik B, Moerman EJ, Grant DF, et al., Divergent effects of selective peroxisome proliferator-activated receptor- γ 2 ligands on adipocyte versus osteoblast differentiation, *Endocrinology*, 2002;143:2376–84.
18. Soroceanu MA, Miao D, Bai XY, et al., Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis, *J Endocrinol*, 2004;183:203–16.
19. Ali AA, Weinstein RS, Stewart SA, et al., Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation, *Endocrinology*, 2005;146:1226–35.
20. Kahn SE, Haffner SM, Heise MA, et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, *N Engl J Med*, 2006;355:2427–43.
21. Grey A, Bolland M, Gamble G, et al., The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial, *J Clin Endocrinol Metab*, 2007;92:1305–10.
22. Wild S, Roglic G, Green A, et al., Global prevalence of diabetes, *Diabetes Care*, 2004;27:1047–53.